Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

Background Olanzapine 10 mg added to standard antiemetic therapy including aprepitant,
palonosetron, and dexamethasone has been recommended for the prevention of …

Purpose To update the American Society of Clinical Oncology (ASCO) guideline for
antiemetics in oncology. Methods A systematic review of the medical literature was …

Polysorbate 80 is a synthetic nonionic surfactant used as an excipient in drug formulation.
Various products formulated with polysorbate 80 are used in the oncology setting for …

Patients with cancer should appropriately receive antiemetic therapies against
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …

Purpose: Consensus guidelines for preventing chemotherapy-induced nausea and vomiting
(CINV) are variably implemented in practice. The purpose of this study was to evaluate the …

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant
deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated …

Purpose This review summarizes the recommendations for the prophylaxis of nausea and
vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes …